What is HC Wainwright’s Estimate for MNMD FY2029 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMDFree Report) – HC Wainwright issued their FY2029 EPS estimates for Mind Medicine (MindMed) in a note issued to investors on Friday, January 31st. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $2.84 for the year. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMDGet Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. During the same quarter last year, the business earned ($0.53) EPS.

Several other equities analysts have also recently issued reports on MNMD. Leerink Partnrs upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Friday, October 11th. Chardan Capital initiated coverage on shares of Mind Medicine (MindMed) in a research report on Friday, December 20th. They issued a “buy” rating and a $20.00 price target on the stock. Evercore ISI started coverage on shares of Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They set an “outperform” rating and a $23.00 price objective for the company. Leerink Partners began coverage on shares of Mind Medicine (MindMed) in a report on Monday, October 14th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, Oppenheimer restated an “outperform” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Ten investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $26.33.

View Our Latest Research Report on Mind Medicine (MindMed)

Mind Medicine (MindMed) Trading Up 8.5 %

Shares of NASDAQ MNMD opened at $7.37 on Monday. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09. The stock’s 50 day moving average price is $7.26 and its two-hundred day moving average price is $6.90. Mind Medicine has a 52-week low of $3.85 and a 52-week high of $12.22. The stock has a market capitalization of $540.44 million, a P/E ratio of -3.26 and a beta of 2.59.

Institutional Trading of Mind Medicine (MindMed)

A number of hedge funds have recently made changes to their positions in MNMD. Wealth Enhancement Advisory Services LLC acquired a new position in Mind Medicine (MindMed) in the 3rd quarter valued at approximately $58,000. Sanctuary Advisors LLC acquired a new stake in Mind Medicine (MindMed) during the third quarter valued at $91,000. Foundations Investment Advisors LLC purchased a new position in Mind Medicine (MindMed) in the fourth quarter valued at about $91,000. Stoneridge Investment Partners LLC acquired a new position in Mind Medicine (MindMed) in the 3rd quarter worth about $93,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Mind Medicine (MindMed) during the 3rd quarter worth about $93,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Mind Medicine (MindMed) news, insider Dan Karlin sold 6,643 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $7.43, for a total transaction of $49,357.49. Following the completion of the sale, the insider now directly owns 338,013 shares of the company’s stock, valued at approximately $2,511,436.59. This represents a 1.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert Barrow sold 19,106 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total transaction of $141,957.58. Following the sale, the chief executive officer now directly owns 526,666 shares in the company, valued at approximately $3,913,128.38. This trade represents a 3.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,022 shares of company stock worth $208,203 over the last ninety days. Company insiders own 2.26% of the company’s stock.

Mind Medicine (MindMed) Company Profile

(Get Free Report)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.

Further Reading

Earnings History and Estimates for Mind Medicine (MindMed) (NASDAQ:MNMD)

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.